Melanie Senior
Sanofi-Aventis’ rimonabant (Acomplia) was never going to fit neatly into any of the industry’s pre-defined categories. Approved in Europe in...
The Acomplia Paradox: Primary Care Drug, Targeted Population
As Acomplia is launched across Europe, Sanofi Aventis' challenge is less about promoting the drug, than about limiting its use within the appropriate target group.
More from Archive
More from In Vivo
• By
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
• By
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
• By
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.